Document Detail


Patterns of medication use during pregnancy in rheumatoid arthritis.
MedLine Citation:
PMID:  21557526     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVE: To characterize therapies prescribed during pregnancy to women with rheumatoid arthritis (RA).
METHODS: We conducted a cohort study of women with RA with pregnancies using health care utilization data from 2002-2008. We examined the distribution of RA drugs by therapeutic classes, including nonsteroidal antiinflammatory drugs (NSAIDs)/coxibs, glucocorticoids, nonbiologic disease-modifying antirheumatic drugs (DMARDs), and biologic DMARDs, during 90-day pregnancy trimesters and the 180 days prior to pregnancy. Drugs were characterized according to the Food and Drug Administration risk classification system. Differences in exposure by period were determined by chi-square tests.
RESULTS: A total of 393 pregnancies were identified among 34,169 women with RA. Seventy-two percent of pregnancies ended in a delivery. Approximately 24% of women with RA received a DMARD during preconception. At any point during pregnancy, 23% of women with deliveries were dispensed ≥1 DMARD and the proportion of use declined from the first to the third trimester (P = 0.03). Similar to DMARD therapy, use of NSAIDs/coxibs and exposure to category D/X medications were significantly lower compared to prepregnancy use (P < 0.05). In contrast, more women were prescribed glucocorticoids during pregnancy than before pregnancy. Use of biologics occurred in 12.5% of pregnancies. Compared to women with deliveries, women who experienced abortions were more frequently exposed to NSAIDs/coxibs (P < 0.05). Dispensing of category D/X medications was also higher in women with spontaneous abortions and primarily involved methotrexate (P < 0.05).
CONCLUSION: Approximately 24% of women with RA received a DMARD in the 180 days before conception, and the proportion dropped during pregnancy. Glucocorticoid use remained high throughout pregnancy. Our results suggest that continued efforts directed at counseling women and their physicians about the potential risks/benefits of RA therapies during pregnancy are warranted.
Authors:
Bindee Kuriya; Sonia Hernández-Díaz; Jun Liu; Bonnie L Bermas; Gregory Daniel; Daniel H Solomon
Related Documents :
21125366 - Prevalence and risk factors for gastroesophageal reflux in pregnancy.
21105016 - Magnetic resonance imaging of the placenta identifies placental vascular abnormalities ...
21299396 - Suggested algorithm for cytomegalovirus surveillance in low-risk pregnancies.
21404306 - First trimester pregnancy-associated plasma protein-a in pregnancies complicated by sub...
9820926 - Quinacrine sterilization: an assessment of risks for ectopic pregnancy, birth defects a...
8008176 - Creutzfeldt-jakob disease in a pregnant woman with an implanted dura mater graft.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Arthritis care & research     Volume:  63     ISSN:  2151-4658     ISO Abbreviation:  Arthritis Care Res (Hoboken)     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101518086     Medline TA:  Arthritis Care Res (Hoboken)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  721-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 by the American College of Rheumatology.
Affiliation:
Harvard School of Public Health, Boston, Massachusetts. bindee.kuriya@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis p...
Next Document:  Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile l...